Skip Navigation

European Heart Journal 2004 25(18):1562-1564; doi:10.1016/j.ehj.2004.07.024
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Montalescot, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montalescot, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?

Gilles Montalescot*

Institut de of Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France

* Correspondence to: Professor Gilles Montalescot MD, PhD, Institut de of Cardiologie, Hôpital Pitié-Salpêtrière, Bureau 2-236, 47 Bl de l'Hôpital, 75013 Paris, France. Tel.: +33 1 4216 3006; fax: +33 1 4216 2931 (E-mail: gilles.montalescot@psl.ap-hop-paris.fr).

The first 10% of the full text of this article appears below.

This editorial refers to "Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting"{dagger} by G. Ndrepepa et al. on page 1635

Over the years, several controversies have surrounded the choices made before and during the reperfusion process of acute ST-elevation myocardial infarction (STEMI). Among many others, questions have been raised over the value of percutaneous coronary intervention (PCI) versus thrombolysis, of stenting versus balloon angioplasty, of filters or thrombectomy devices versus no distal protection, and of course, of glycoprotein (GP) IIb/IIIa inhibitors versus no GP IIb/IIIa inhibitors. Among the dozen of randomized trials evaluating these drugs in primary PCI of evolving STEMI, only five were big enough to look at clinical endpoints and were performed with abciximab. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting
Gjin Ndrepepa, Adnan Kastrati, Franz-Josef Neumann, Claus Schmitt, Julinda Mehilli, and Albert Schömig
EHJ 2004 25: 1635-1640. [Abstract] [Full Text]